Introduction {#Sec1}
============

Percutaneous coronary intervention (PCI) is extensively used as a reperfusion strategy for coronary artery disease. Although this procedure is relatively safe and the procedure-related complications have markedly decreased with years, peri-procedural myocardial injury (PMI) can still occur \[[@CR1]\]. The most common mechanism is side-branch occlusion during PCI, and distal embolism, coronary dissection, and inflammation can also result in PMI. Moreover, PMI lead to an increased incidence of death at follow-up (hazard ratio\[HR\] = 1.2, 95 % CI: 1.04-1.39) after adjustment for baseline covariates \[[@CR2]\]. Research previously focused on the improvement of antithrombotic agents and vasodilators in decreasing the incidence of cardiac ischemic events during PCI, while recently it was found that pretreatment with statins may significantly reduce major adverse cardiac events (MACE) and PMI in patients undergoing PCI \[[@CR3], [@CR4]\]. It has already been proved in some meta-analyses of randomized controlled trials (RCTs) \[[@CR5], [@CR6]\]. A meta-analysis of 3341 individuals from 13 randomized studies suggested that statin preloading leads to a significant decrease in 30-day MACE and PMI in patients undergoing PCI \[[@CR5]\]. However, this research was not able to indicate whether statin pretreatment was effective in stable angina or acute coronary syndrome (ACS) patients, as patients were not assigned to subgroups according to their clinical presentation. Another updated meta-analysis comprising 5526 patients from 24 RCTs indicated that the cardioprotective benefits of statin preloading on MACE were effective for statin naïve or ACS patients \[[@CR7]\]. However, recent published trials in which patients received high-dose rosuvastatin treatment prior to PCI were not included in this study, and this may have influenced the final clinical outcomes.

Rosuvastatin (RSV), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, has a number of pleiotropic effects, including antioxidative, antithrombotic, anti-inflammatory, and cardiovascular protective outcomes. Recently, investigators found a lower rate of MACE and PMI when patients undergoing PCI received high-dose RSV pretreatment \[[@CR8]--[@CR21]\]. However, most of the prospective trials lacked the power to detect differences from clinical outcomes, due to small size, varying endpoint definitions, individuals with different clinical presentation, and diverse regimens of RSV therapy. Therefore, we systematically evaluated the clinical benefits of high-dose RSV preloading prior to PCI by conducting a meta-analysis including all relevant RCTs.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

In this study, we searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials and ISI Web of Science databases up to June 2015 to determine prospective RCTs comparing the cardiovascular events of RSV preloading with control (placebo, no-statin, or current statin therapy) in patients undergoing PCI. Key words for searching were: "rosuvastatin", "percutaneous coronary intervention", "PCI", "stents", "angioplasty", "randomized" and "randomly". We also screened previous meta-analyses and the references of selected studies. No language restrictions were used.

Study selection {#Sec4}
---------------

Trials were included if: (1) they were RCTs involving humans; (2) they selected patients with ACS (ST-segment elevation myocardial infarction \[STEMI\], unstable angina pectoris, or non-ST-segment elevation myocardial infarction \[NSTEMI\]) or stable angina; (3) they enrolled patients who were statin naïve or undergoing current therapy with statins; (4) they reported information on MACE including mortality, spontaneous myocardial infarction (MI), and target vessel revascularization (TVR) as well as PMI after PCI. Thrombolysis in myocardial infarction (TIMI) classification post-PCI was also recorded. Exclusion criteria included: (1) non-randomized controlled trials; (2) no outcomes of interest; (3) duplicate reports without additional or updated outcome data.

Data extraction {#Sec5}
---------------

Two authors (YLP and YT) extracted the data in all the included trials, and any disagreement was resolved by discussion with the third author (BL). Firstly, the following information was extracted from each study: the first author's name, year of publication, sample size of the trial, type of population, clinical features, regimen of statins before and after PCI, study duration, and definition of PMI. Furthermore, we extracted the baseline characteristics and procedural details in all enrolled patients. Finally, we extracted data according to the clinical outcomes including mortality, spontaneous MI, TVR, and overall MACE during the follow-up period in each group.

Quality assessment {#Sec6}
------------------

Study quality was evaluated based on the quality assessment criteria for RCTs in the Cochrane Handbook for Systematic Reviews of Interventions, including random sequence generation, allocation concealment, blinding of investigators, participants and outcome assessors, incomplete outcome data, selective reporting and other sources of bias.

End-Points {#Sec7}
----------

The primary end-points were MACE and PMI. We used the PMI definition which was taken from the original articles. Secondary end-point was final TIMI flow grade, which assessed myocardial perfusion after PCI. We carried out sub-group analyses according to the clinical condition (ACS and stable angina) or current statin therapy (statin naïve and previous statin therapy).

Statistics {#Sec8}
----------

Odds ratio (OR) with 95 % confidence intervals (CI) was used to express dichotomous variables, such as the incidence of PMI, MACE, and post-PCI TIMI flow 3. Heterogeneity among studies was quantified using the *I*^2^ statistic, defined as *I*^2^ \> 50 %. In that case, the random effects model was used; otherwise, the fixed effect model was chosen. Funnel plots and Egger's regression test were used to illustrate the potential publication bias. Results were considered statistically significant at *P* \< 0.05. RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark) was used for statistical analysis.

Results {#Sec9}
=======

Selected studies and baseline characteristics {#Sec10}
---------------------------------------------

Based on the search strategy described above, 366 potentially relevant studies were initially included by titles and abstracts (Fig. [1](#Fig1){ref-type="fig"}), and 28 publications were selected. After reading the full texts of these publications, fourteen further studies were excluded as they were either duplicate studies, no outcome of interest reported, or were non-randomized studies. Finally, 3273 individuals from fourteen RCTs \[[@CR8]--[@CR21]\] were included, of which 1671 were randomized to the high-dose RSV group and 1602 were randomized to control.Fig. 1Flow diagram of study selection process. RCTs, randomized controlled trials

Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of all the studies, which were published between 2010 and 2014. There were ten trials \[[@CR8], [@CR10], [@CR11], [@CR13], [@CR15], [@CR17]--[@CR21]\] with only statin naïve patients, one trial \[[@CR16]\] with only previous statin therapy patients, and three trials \[[@CR9], [@CR12], [@CR14]\] with both of two. Five trials \[[@CR9], [@CR14]--[@CR16], [@CR21]\] included stable angina patients, six trials \[[@CR8], [@CR11], [@CR13], [@CR17], [@CR19], [@CR20]\] included NSTE-ACS patients, two trials \[[@CR12], [@CR18]\] included STEMI patients, and one trial \[[@CR10]\] included ACS patients. Thirteen trials \[[@CR8]--[@CR13], [@CR15]--[@CR21]\] included short-term RSV pretreatment (immediate to 24 h), while one trial \[[@CR14]\] included relatively long-term RSV pretreatment (5 to 7 days). Other characteristics of the included studies were follow-up duration and definition of PMI. The baseline characteristics of the patients and the procedural details in all trials are shown in Table [2](#Tab2){ref-type="table"}. Approximately two-thirds of the overall population were male, three-fifths of those had hypertension, and one-third of those had diabetes. Preprocedural aspirin and clopidogrel were given to patients in all studies, and patients among four trials \[[@CR11], [@CR12], [@CR15], [@CR16]\] received a loading dose of clopidogrel (600 mg), while the number of patients treated with clopidogrel in one trial \[[@CR10]\] were unclear. Patients in a total of 11 trials \[[@CR8], [@CR11]--[@CR13], [@CR15]--[@CR21]\] received glycoprotein IIb/IIIa inhibitors (GPIs) at the operators' discretion, while the remaining trials \[[@CR9], [@CR10], [@CR14]\] did not mention the use of GPIs. Almost four-fifths of the patients in seven trials \[[@CR8], [@CR10], [@CR13], [@CR15], [@CR17], [@CR20], [@CR21]\] underwent implantation of drug-eluting stents.Table 1Characteristics of the included studiesStudyPatients (RSV/ Con)Type of populationClinical featureTiming before PCIRegimen after PCIFollow-upDefinition of PMIGao \[[@CR19]\]59/58Statin naïveNSTE-ACSRSV 20 mg 12 h and 10 mg 2 h before PCI VS placebo treatmentRSV 10 mg/d for at least 1 year6 monthsCKMB \> 3 UNLLi \[[@CR18]\]103/ 100Statin naïveSTEMIRSV 20 mg before PCI VS RSV 10 mg treatmentRSV 10 mg/d for 3 months30 daysCKMB \> 3 UNLLuo \[[@CR17]\]31/36Statin naïveNSTE-ACSRSV 20 mg 12 h and 20 mg 2 h before PCI VS no statin pretreatmentRSV 10 mg/d30 dayscTnI \> 3 UNLTakano \[[@CR14]\]104/ 106MixedStable AnginaRSV 20 mg 5-7day before PCI VS RSV 2.5 mg treatmentRSV 10 mg/d VS RSV 2.5 mg/d12 monthsCKMB \> 3 UNLWang \[[@CR13]\]62/63Statin naïveNSTE-ACSRSV 20 mg before PCI VS placebo pretreatmentRSV 10 mg/d for at least 30 days30 daysCKMB \> 3 UNLXie \[[@CR8]\]79/80Statin naïveNSTE-ACSRSV 20 mg 12 h and 20 mg 2 h before PCI VS placebo treatmentRSV 10 mg/d30 dayscTnI \> 5 UNLYun \[[@CR20]\]225/ 220Statin naïveNSTE-ACSRSV 40 mg before PCI VS no statin pretreamentRSV 10 mg/d12 monthsCKMB \> 2 UNLVeselka \[[@CR9]\]220/ 225MixedStable AnginaRSV 20 mg 12 h and 20 mg before PCI VS no statin pretreatmentStatin treatmentIn hospitalcTnI \> 5 UNLCay \[[@CR21]\]153/ 146Statin naïveStable AnginaRSV 40 mg 24 h before PCI VS no RSV pretreatmentRSV 10-40 mg/dIn hospitalCKMB \> 3 UNLLeoncini \[[@CR11]\]252/ 252Statin naïveNSTE-ACSRSV 40 mg 24 h and 20 mg before PCI VS no statin pretreatmentRSV 20 mg/d VS atorvastatin 40 mg/d6 monthsCKMB \> 3 UNLROMA \[[@CR16]\]80/80Statin naïveStable AnginaRSV 40 mg 24 h before PCI VS no RSV pretreatmentRSV 20 mg/d12 monthsCKMB \> 3 UUNLROMAII \[[@CR15]\]175/ 100prior statin treatmentStable AnginaRSV 40 mg 24 h before PCI VS no statin pretreatmentRSV 20 mg/d12 monthsCKMB \> 3 UNLKo \[[@CR12]\]62/70MixedSTEMIRSV 40 mg before PCI VS placebo treatmentRSV 40 mg VS 10 mg both for 7 days, and a further 10 mg/d in both groups for 3 weeks3 monthsNALiang \[[@CR10]\]66/66Statin naïveACSRSV 40 mg 4 h VS RSV 10 mg before PCIRSV 10 mg/d for at least 1 year6 monthsNA*RSV* rosuvastatin, *CK-MB* creatine kinase-myocardial band, *cTnI* cardiac troponin I, *UNL* upper normal limit, *Mixed* Statin naïve and prior statin treatment, *PMI* periprocedural myocardial infarction, *ACS* acute coronary syndrome, *NSTE-ACS* non-ST segment elevation ACS, *STEMI* ST segment elevation myocardial infarction, *NA* not availableTable 2Baseline clinical characteristics and procedural details in the overall populationVariablesHigh-dose of RSV n/population (%)Control n/population (%)Number of patients1671/3273 (51.1 %)1602/3273 (48.9 %)Male1150/1671 (68.8 %)1075/1602 (67.1 %)Hypertension1088/1671 (65.1 %)988/1602 (61.7 %)Diabetes Mellitus473/1671 (28.3 %)449/1602 (28.0 %)Smoker592/1606 (36.9 %)573/1542 (37.2 %)Previous MI223/1067 (20.9 %)224/1069 (21.0 %)Previous PCI160/1019 (15.7 %)143/1017 (14.1 %)Stable angina732/1671 (43.8 %)657/1602 (41.0 %)NSTEMI759/1671 (45.4 %)759/1602 (47.3 %)STEMI181/1671 (10.8 %)188/1602 (11.7 %)Multi-vessel disease198/644 (30.7 %)157/633 (24.8 %)B2/C lesions654/918 (71.2 %)590/855 (69.0 %)Thrombus122/757 (16.1 %)135/763 (17.7 %)LM16/700 (2.3 %)25/709 (3.5 %)LAD666/1253 (53.2 %)619/1174 (52.7 %)LCX360/1315 (27.3 %)354/1244 (28.4 %)RCA393/1253 (31.4 %)368/1174 (31.3 %)Multiple vessel PCI216/644 (33.5 %)203/768 (26.4 %)Aspirin1624/1671 (97.2 %)1548/1602 (96.6 %)Clopidogrel1599/1605 (99.6 %)1530/1536 (99.6 %)β-blockers952/1393 (68.3 %)979/1402 (69.8 %)ACEI/ARB910/1393 (65.3 %)953/1402 (67.9 %)Glycoprotein IIb/IIIa inhibitors76/1025 (7.4 %)103/959 (10.7 %)Numbers of DES560/696 (80.5 %)556/691 (80.5 %)*Previous MI* previous myocardial infarction, *Previous PCI* previous percutaneous coronary intervention, *NSTE-ACS* non-ST segment elevation acute coronary syndrome, *STEMI* ST segment elevation myocardial infarction, *LM*, left main, *LAD* left anterior descending, *LCX* left circumflex, *RCA* right coronary artery, *DES* drug-eluting stent

Judgments on each risk of bias item for all studies are shown in Fig. [2](#Fig2){ref-type="fig"}. Five of fourteen trials \[[@CR10], [@CR12], [@CR15], [@CR16], [@CR19]\] reported the specific methods used for randomization, while the remaining included trials \[[@CR8], [@CR9], [@CR11], [@CR13], [@CR14], [@CR17], [@CR18], [@CR20], [@CR21]\] did not mention that. Three trials \[[@CR10], [@CR12], [@CR15]\] described the allocation concealments in detail, two trials \[[@CR11], [@CR14]\] did not use allocation concealments, and allocation concealments were not described in the remaining trials.\[[@CR8], [@CR9], [@CR13], [@CR16]--[@CR21]\] Blinded methods were used in four trials, three of which \[[@CR10], [@CR12], [@CR13]\] used a blinded approach for investigators, participants and outcome assessors, while one trial \[[@CR17]\] was only blinded for outcome assessors. None of the included studies had incomplete outcome data, selective reporting and other sources of bias.Fig. 2Quality assessment of included studies in this review **a**. Risk of bias graph; **b**. Risk of bias summary

Effect of high-dose RSV preloading before PCI on coronary perfusion {#Sec11}
-------------------------------------------------------------------

Effect of high-dose RSV preloading before PCI on post-PCI TIMI flow grade 3 were analyzed in ten trials \[[@CR9], [@CR10], [@CR13]--[@CR15], [@CR17]--[@CR21]\]. Fixed effect model was chosen based on no potential heterogeneity across trials (*I*^2^ = 0 %, *P* = 0.91). The overall outcome indicated that RSV preloading lead to a 61 % relative increase in post-PCI TIMI flow grade 3 (OR = 1.61, 95 % CI: 1.09-2.38, *P* = 0.02; Fig. [3](#Fig3){ref-type="fig"}).Fig. 3ORs for final TIMI flow grade in overall population. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Effect of high-dose RSV preloading before PCI on clinical outcomes {#Sec12}
------------------------------------------------------------------

Effect of high-dose RSV preloading before PCI on MACE were analyzed in 12 trials \[[@CR8], [@CR10]--[@CR20]\]. Fixed effect model was chosen based on no potential heterogeneity across trials (*I*^2^ = 0 %, *P* = 0.89). The overall outcome for MACE showed that RSV preloading lead to a 58 % relative reduction in MACE (OR = 0.42, 95 % CI: 0.29-0.61, *P* \< 0.00001; Fig. [4](#Fig4){ref-type="fig"}). Effect of RSV preloading before PCI on PMI were analyzed in 12 trials \[[@CR8], [@CR9], [@CR11], [@CR13]--[@CR21]\]. Random effects model was used due to substantial heterogeneity between the two groups (*I*^2^ = 53 %, *P* = 0.01). The overall outcome for PMI showed that RSV preloading lead to a 60 % relative reduction in PMI (OR = 0.40, 95 % CI: 0.25-0.63, *P* \< 0.0001; Fig. [5](#Fig5){ref-type="fig"}).Fig. 4ORs for MACE in patients with different coronary syndromes. Abbreviations: CI, confidence interval; M-H, Mantel-HaenszelFig. 5ORs for PMI in patients with different coronary syndromes. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Subgroup analyses with different types of coronary syndrome {#Sec13}
-----------------------------------------------------------

In order to assess the effect of high-dose RSV preloading in patients with different disease status before undergoing PCI, we divided all enrolled patients into two groups: stable angina and ACS. Due to the fixed effect model, RSV preloading before PCI lead to a 58 % relative reduction in MACE for stable angina patients (OR = 0.42, 95 % CI: 0.21-0.87, *P* = 0.02; *I*^2^ = 10 %); and a 58 % relative reduction in MACE for ACS patients (OR = 0.42, 95 % CI: 0.27-0.65, *P* \< 0.0001; *I*^2^ = 0 %) (Fig. [4](#Fig4){ref-type="fig"}). We also evaluated the stable angina and ACS subgroup for their effects on PMI. Due to the random effects model, RSV preloading before PCI lead to a 63 % reduction in PMI for stable angina patients (OR = 0.37, 95 % CI: 0.14-0.97, *P* = 0.04; *I*^2^ = 81 %); and a 57 % reduction in PMI for ACS patients (OR = 0.43, 95 % CI: 0.29-0.65, *P* \< 0.0001; *I*^2^ = 0 %) (Fig. [5](#Fig5){ref-type="fig"}).

Subgroup analyses based on previous statin therapy {#Sec14}
--------------------------------------------------

In order to confirm whether current statin therapy before high-dose RSV preloading prior to PCI affected the incidence of MACE and PMI, we evaluated subgroups of patients based on their statin therapy before PCI in 11 trials \[[@CR8], [@CR10], [@CR11], [@CR13]--[@CR20]\]. Due to the fixed effect model, RSV preloading lead to a 60 % relative reduction of MACE in all the enrolled patients (OR = 0.40, 95 % CI: 0.27-0.58, *P* \< 0.00001; *I*^2^ = 0 %), a 58 % relative reduction in the statin naïve group (OR = 0.42, 95 % CI: 0.28-0.64, *P* \< 0.0001; *I*^2^ = 0 %) and a 72 % relative reduction in the previous statin therapy group (OR = 0.28, 95 % CI: 0.10-0.73, *P* = 0.01; *I*^2^ = 0 %) (Fig. [6](#Fig6){ref-type="fig"}). Due to the fixed effect model, RSV preloading lead to a 67 % relative reduction of PMI in all the enrolled patients (OR = 0.33, 95 % CI: 0.25-0.45, *P* \< 0.00001; *I*^2^ = 0 %), a 66 % relative reduction in the statin naïve group (OR = 0.34, 95 % CI: 0.24-0.49, *P* \< 0.00001; *I*^2^ = 0 %), and a 69 % relative reduction in the previous statin therapy group (OR = 0.31, 95 % CI: 0.17-0.55, *P* \< 0.0001; *I*^2^ = 39 %) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 6ORs for MACE in patients with different statin therapy. Abbreviations: CI, confidence interval; M-H, Mantel-HaenszelFig. 7ORs for PMI in patients with different statin therapy. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel

Effects of high-dose RSV preloading on follow-up outcome {#Sec15}
--------------------------------------------------------

**Table**[3](#Tab3){ref-type="table"} depicts overall MACE including mortality, spontaneous MI, and TVR during follow-up. As mentioned above, the overall MACE was significantly reduced in all the enrolled patients. When stratified by type of disease, high-dose RSV preloading before PCI failed to decrease overall mortality (*P* = 0.42), spontaneous MI (*P* = 0.34) and TVR (*P* = 0.05) in patients with stable angina, and also didn't reduce overall mortality in ACS patients (*P* = 0.09). However, RSV preloading before PCI significantly reduced the incidence of spontaneous MI (*P* = 0.02) and TVR (*P* = 0.01) in ACS patients. According to previous statin therapy, high-dose RSV preloading had no influence on overall mortality (*P* = 0.3), spontaneous MI (*P* = 0.13) and TVR (*P* = 0.09) in previous statin therapy patients. Moreover, the overall mortality (*P* = 0.09) was not significantly reduced in statin naïve patients, while the incidence of spontaneous MI (*P* = 0.02) and TVR (*P* = 0.008) was significantly decreased.Table 3Clinical events during follow-upEventsHigh-dose of RSV n (%)Control n (%)PStable Death2(0.6 %)3(1.0 %)0.42 Spontaneous MI5(1.4 %)7(2.4 %)0.34 TVR5(1.4 %)12(4.2 %)0.05 MACE12(3.3 %)22(7.7 %)0.02ACS Death7(0.7 %)15(1.6 %)0.09 Spontaneous MI7(0.7 %)20(2.1 %)0.02 TVR19(2.0 %)37(3.9 %)0.01 MACE33(3.5 %)72(7.6 %)\<0.0001Overall Death9(0.7 %)18(1.5 %)0.06 Spontaneous MI12(0.9 %)27(2.2 %)0.01 TVR24(1.8 %)49(4.0 %)0.002 MACE45(3.5 %)94(7.6 %)\<0.00001Statin naïve Death7(0.7 %)15(1.6 %)0.09 Spontaneous MI8(0.8 %)21(2.2 %)0.02 TVR20(2.1 %)40(4.2 %)0.008 MACE35(3.7 %)76(8.0 %)\<0.0001Prior statin treatment Death1(0.4 %)2(1.2 %)0.3 Spontaneous MI2(0.8 %)5(3.0 %)0.13 TVR3(1.2 %)7(4.2 %)0.09 MACE6(2.4 %)14(8.4 %)0.01Overall Death8(0.7 %)17(1.5 %)0.05 Spontaneous MI10(0.8 %)26(2.3 %)0.005 TVR23(1.9 %)47(4.2 %)0.002 MACE41(3.4 %)90(8.0 %)\<0.00001*ACS* acute coronary syndrome, *Spontaneous MI* spontaneous myocardial infarction, *TVR* target vessel revascularization, *MACE* major adverse cardiovascular events

Publication bias {#Sec16}
----------------

As shown in Fig. [8](#Fig8){ref-type="fig"}, the results didn't provide any evidence of potential publication bias based on funnel plots and Egger's regression test. Funnel plots for MACE were generated using a fixed effect model (*P* = 0.139 \> 0.05) and for PMI were generated using a random effects model (*P* = 0.273 \> 0.05).Fig. 8Funnel plots of the included studies. **a**. Funnel plots for MACE; **b**. Funnel plots for PMI. The results show no potential publication bias for MACE and PMI. Abbreviations: OR, odds ratio; SE, standard error

Discussion {#Sec17}
==========

Our analysis of 3273 individuals from 14 RCTs demonstated that high-dose RSV preloading before PCI can significantly improve the post-PCI TIMI flow grade and reduce the incidence of MACE and PMI. In addition, according to different disease presentations, high-dose RSV preloading can significantly decrease the incidence of MACE and PMI in both stable angina and ACS patients; when stratified according to current statin therapy, high-dose RSV preloading can also significantly reduce the incidence of MACE and PMI in both statin naïve and previous statin therapy patients. Moreover, according to the follow-up data, high-dose RSV preloading can significantly reduce the incidence of spontaneous MI and TVR in ACS and statin naïve patients, but failed to improve clinical outcomes in both patients with stable angina and current statin therapy.

We confirm and extend the meta-analyses by Benjo A.M \[[@CR22]\] and Wang L \[[@CR7]\] which indicated a reduction in PMI and MACE with statin preloading before PCI. Benjo *et al.* selected 1591 patients from 14 RCTs and found a 56 % relative reduction in PMI and a 41 % reduction in clinical events in patients with current statin treatment before PCI. Wang L *et al.* selected 24 RCTs with 5526 patients and demonstrated that statin preloading lead to a 59 % relative reduction in PMI and a 39 % relative reduction in MACE. These two studies were credible and conclusive, while different types of statins may have various effects on clinical events in both studies. Although the former study was powerful and proved their hypothesis, patients with STEMI and current statin treatment were excluded, which led to the lack of identifying the effects of statin preloading in the overall population. Data on patients with chronic statin therapy were included in the latter study, however, recent trials on high-dose RSV pretreatment, which were published after this meta-analysis, drew controversial conclusions concerning the cardioprotective benefits of this treatment on PMI and MACE. Our meta-analysis demonstrated that RSV preloading before PCI lead to a 60 % relative reduction in PMI (*P* \< 0.0001) and a 58 % relative reduction in MACE (*P* \< 0.00001). The cardioprotective effects of RSV were consistent in not only stable angina and ACS patients but also statin naïve and previous statin therapy patients. High-dose RSV preloading can significantly reduce the clinical outcome in the overall population, which was mainly due to a reduction of TVR, especially for ACS and statin naïve patients. Although these benefits of RSV preloading failed to decrease overall mortality in the enrolled patients, they reduced the incidence of spontaneous MI and TVR in ACS and statin naïve patients.

PMI is characterized by any cardiac serum marker (creatine kinase-myocardial band \[CK-MB\]; cardiac troponin I \[cTnI\]) elevation three times or more the upper limit of normal (ULN) after PCI, which has been shown to occur in approximately 15-20 % of patients undergoing PCI procedures in spite of different definitions used \[[@CR23]\]. The pathogenic mechanisms of PMI include side-branch occlusion, distal embolism, endothelial dysfunction, oxidative stress, and inflammation \[[@CR1]\]. In order to reduce the incidence of PMI, researchers have focused on antiplatelet agents, anticoagulants, vasodilators, and beta-blockers to improve coronary blood flow after PCI. More recently, some studies \[[@CR21], [@CR24], [@CR25]\] have suggested that the reduction of the MACE and PMI in patients undergoing PCI was associated with HMG-CoA reductase inhibitors (statins), in particular atorvastatin and RSV. In addition to its lipid-lowering effects, RSV exerts many cardioprotective effects including an improvement in endothelial function, antithrombotic actions, inhibition of thrombosis, plaque stabilization, and suppression of inflammation. These may partly account for the cardioprotective effects of RSV on spontaneous MI and TVR in ACS patients due to the high inflammatory status in these patients, which is associated with a high predictive value for the occurrence of MACE \[[@CR26]\].

The possible mechanisms underlying the early protective action of RSV are unclear, as the enrolled patients were given a short-term high-dose of RSV before PCI, which may not have had a significant influence on cholesterol level. Vilahur G *et al.* \[[@CR27]\] showed that RSV enhanced PKC, Erk2, AKT/PKB signal pathways and its downstream effectors to attenuate inflammation and cardiomyocyte apoptosis in the peri-infarcted zone and reduce infarct size in pigs. RSV has been shown to enhance the protective effects of ischemic post-conditioning against myocardial ischemia and reperfusion (I/R) injury in rats via activating PI3K/Akt/eNOS signaling pathway \[[@CR28]\]. Nitrous oxide (NO), due to the activation of endothelial nitric oxide synthase (eNOS), can decrease leukocyte activation and infiltration, platelet activation and aggregation, vasoconstriction and contractile dysfunction \[[@CR1]\]. These beneficial cardiac effects of statins are absent in eNOS knockout mice and can be reversed by using the specific inhibitor of PI3K kinase and eNOS \[[@CR29], [@CR30]\]. In our meta-analysis, cardiac benefits of high-dose RSV preloading before PCI decreased the incidence of spontaneous MI and TVR in statin naïve patients, but had no effects on previous statin therapy patients. Patients with previous statin therapy are probably in a condition of dyslipidaemia. They are likely to take some nutraceuticals (resveratrol, grape seed, curcumin, zinc, and fish oil) and antioxidants (carotenoids, vitamins A, C, and E) in their daily diet to decrease the plasma lipids, which can influence the overall outcomes \[[@CR31], [@CR32]\]. Hence, we speculate that the cardiovascular benefits of short-term high-dose RSV preloading might be counteracted by long-term intake of statin, nutraceuticals, or antioxidants. Interestingly, chronic statin therapy failed to exert a cardioprotective effect that wanes with time associated with increased levels of PTEN (phosphatase and tensin homolog deleted on chromosome ten, an inhibitor of PI3K) in SD rats and these can partly attenuate the cardioprotective effects of high-dose RSV preloading, which may partially confirm our speculation \[[@CR33]\].

The results of our study are different from those by Veselka *et al.* \[[@CR9]\], who demonstrated that high-dose RSV therapy had no effects on the incidence of PMI in patients with stable angina. We compared the results when included and excluded Veselka's trial data. The significant effects on PMI were unchanged, while excluding Veselka's data changed the homogeneity in the stable angina group (*I*^2^ = 81 to 16 %) and the overall population (*I*^2^ = 53 to 0 %). We indicated that the main heterogeneity was due to the different doses and types of statins administered. 36 of 220 patients (16.4 %) in the high-dose RSV group and 51 of 225 patients (22.6 %) in control received long-term high-dose statin therapy (atorvastatin 40 or 80 mg, RSV 20 or 40 mg). This may partially explain why high-dose RSV treatment before PCI failed to reduce the incidence of PMI in their study, as the beneficial cardioprotection effect of transient high-dose RSV may be eliminated by chronic high-dose statin therapy.

Statin therapy is only recommended as secondary prevention of cardiovascular outcomes in the present guidelines for ACS and PCI \[[@CR34], [@CR35]\]. However, high-dose RSV preloading before PCI can reduce the incidence of MACE and PMI, which is not recommended in these guidelines. Our analysis adds strength and power to current recommendations and potentially expands the use of RSV before PCI.

Study limitations {#Sec18}
-----------------

There were several limitations in our meta-analysis. Firstly, the trials included did not use a uniform RSV regimen, definition of PMI, or clinical outcomes examined. Different doses and duration of RSV treatment in patients with different backgrounds may have various effects on MACE and PMI. Secondly, seven of fourteen trials included not long enough follow-up period which was no more than 30 days of observation. Hence, more high quality RCTs are required to identify the beneficial cardiac effects of RSV preloading before PCI over a longer follow-up period. Thirdly, due to a lack of patient-level data, we failed to analyze the effect of high-dose RSV preloading on peri-procedural high-sensitivity C-reactive protein (hs-CRP) level variation (post-intervention hs-CRP minus baseline hs-CRP). In the same way, we are not able to provide subgroup analyses based on gender due to a lack of patient-level data. Hence, further studies are required to investigate whether high-dose RSV preloading plays a different role in men and women. Finally, there was potential heterogeneity in our study due to limited study numbers, small sample sizes, different protocols, and patients with various backgrounds.

Conclusion {#Sec19}
==========

High-dose RSV preloading can significantly improve myocardial perfusion and reduce MACE and PMI in patients undergoing PCI. The cardioprotective effects of RSV preloading were significant in not only stable angina and ACS patients but also statin naïve and previous statin therapy patients. The cardioprotective effects of high-dose RSV were mainly due to the reduction in spontaneous MI and TVR, especially in ACS and statin naïve patients. Therefore, it indicates that RSV preloading before PCI should be used in consideration of the disease presentation and current statin therapy in patients before undergoing PCI.

RSV

:   Rosuvastatin

PCI

:   Percutaneous coronary intervention

PMI

:   Peri-procedural myocardial injury

MACE

:   Major adverse cardiac events

RCTs

:   Randomized controlled trials

MI

:   Myocardial infarction

TVR

:   Target vessel revascularization

HR

:   Hazard ratio

OR

:   Odds ratio

CI

:   Confidence intervals

ACS

:   Acute coronary syndrome

HMG-CoA

:   3-hydroxy-3-methylglutaryl coenzyme A

TIMI

:   Thrombolysis in myocardial infarction

hs-CRP

:   High-sensitivity C-reactive protein

GPIs

:   Glycoprotein IIb/IIIa inhibitors

ULN

:   Upper limit of normal

I/R injury

:   Ischemia and reperfusion injury

NO

:   Nitrous oxide

eNOS

:   Nitric oxide synthase

PTEN

:   Phosphatase and tensin homolog deleted on chromosome ten

CK-MB

:   Creatine kinase-myocardial band

cTnI

:   cardiac troponin I

NSTE-ACS

:   Non-ST segment elevation ACS

STEMI

:   ST segment elevation myocardial infarction

NA

:   Not available

LM

:   Left main

LAD

:   Left anterior descending

LCX

:   Left circumflex

RCA

:   Right coronary artery

DES

:   Drug-eluting stent

M-H

:   Mantel-Haenszel

SE

:   Standard error
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